BACKGROUND: A barrier to statin therapy is myopathy associated with elevated systemic drug exposure. Our objective was to examine the association between clinical and pharmacogenetic variables and statin concentrations in patients. METHODS AND RESULTS: In total, 299 patients taking atorvastatin or rosuvastatin were prospectively recruited at an outpatient referral center. The contribution of clinical variables and transporter gene polymorphisms to statin concentration was assessed using multiple linear regression. We observed 45-fold variation in statin concentration among patients taking the same dose. After adjustment for sex, age, body mass index, ethnicity, dose, and time from last dose, SLCO1B1 c.521T>C (P<0.001) and ABCG2 c.421C>A (P<0.01) were important to rosuvastatin concentration (adjusted R(2)=0.56 for the final model). Atorvastatin concentration was associated with SLCO1B1 c.388A>G (P<0.01) and c.521T>C (P<0.05) and 4β-hydroxycholesterol, a CYP3A activity marker (adjusted R(2)=0.47). A second cohort of 579 patients from primary and specialty care databases were retrospectively genotyped. In this cohort, genotypes associated with statin concentration were not differently distributed among dosing groups, implying providers had not yet optimized each patient's risk-benefit ratio. Nearly 50% of patients in routine practice taking the highest doses were predicted to have statin concentrations greater than the 90th percentile. CONCLUSIONS: Interindividual variability in statin exposure in patients is associated with uptake and efflux transporter polymorphisms. An algorithm incorporating genomic and clinical variables to avoid high atorvastatin and rosuvastatin levels is described; further study will determine whether this approach reduces incidence of statin myopathy.
BACKGROUND: A barrier to statin therapy is myopathy associated with elevated systemic drug exposure. Our objective was to examine the association between clinical and pharmacogenetic variables and statin concentrations in patients. METHODS AND RESULTS: In total, 299 patients taking atorvastatin or rosuvastatin were prospectively recruited at an outpatient referral center. The contribution of clinical variables and transporter gene polymorphisms to statin concentration was assessed using multiple linear regression. We observed 45-fold variation in statin concentration among patients taking the same dose. After adjustment for sex, age, body mass index, ethnicity, dose, and time from last dose, SLCO1B1 c.521T>C (P<0.001) and ABCG2 c.421C>A (P<0.01) were important to rosuvastatin concentration (adjusted R(2)=0.56 for the final model). Atorvastatin concentration was associated with SLCO1B1 c.388A>G (P<0.01) and c.521T>C (P<0.05) and 4β-hydroxycholesterol, a CYP3A activity marker (adjusted R(2)=0.47). A second cohort of 579 patients from primary and specialty care databases were retrospectively genotyped. In this cohort, genotypes associated with statin concentration were not differently distributed among dosing groups, implying providers had not yet optimized each patient's risk-benefit ratio. Nearly 50% of patients in routine practice taking the highest doses were predicted to have statin concentrations greater than the 90th percentile. CONCLUSIONS: Interindividual variability in statin exposure in patients is associated with uptake and efflux transporter polymorphisms. An algorithm incorporating genomic and clinical variables to avoid high atorvastatin and rosuvastatin levels is described; further study will determine whether this approach reduces incidence of statin myopathy.
Authors: Marylyn D Ritchie; Joshua C Denny; Dana C Crawford; Andrea H Ramirez; Justin B Weiner; Jill M Pulley; Melissa A Basford; Kristin Brown-Gentry; Jeffrey R Balser; Daniel R Masys; Jonathan L Haines; Dan M Roden Journal: Am J Hum Genet Date: 2010-04-01 Impact factor: 11.025
Authors: Kathleen M Giacomini; Shiew-Mei Huang; Donald J Tweedie; Leslie Z Benet; Kim L R Brouwer; Xiaoyan Chu; Amber Dahlin; Raymond Evers; Volker Fischer; Kathleen M Hillgren; Keith A Hoffmaster; Toshihisa Ishikawa; Dietrich Keppler; Richard B Kim; Caroline A Lee; Mikko Niemi; Joseph W Polli; Yuichi Sugiyama; Peter W Swaan; Joseph A Ware; Stephen H Wright; Sook Wah Yee; Maciej J Zamek-Gliszczynski; Lei Zhang Journal: Nat Rev Drug Discov Date: 2010-03 Impact factor: 84.694
Authors: Kristian M Bailey; Simon P R Romaine; Beryl M Jackson; Amanda J Farrin; Maria Efthymiou; Julian H Barth; Joanne Copeland; Terry McCormack; Andrew Whitehead; Marcus D Flather; Nilesh J Samani; Jane Nixon; Alistair S Hall; Anthony J Balmforth Journal: Circ Cardiovasc Genet Date: 2010-03-05
Authors: B Tomlinson; M Hu; V W Y Lee; S S H Lui; T T W Chu; E W M Poon; G T C Ko; L Baum; L S Tam; E K Li Journal: Clin Pharmacol Ther Date: 2010-02-03 Impact factor: 6.875
Authors: Liam R Brunham; Steven Baker; Andrew Mammen; G B John Mancini; Robert S Rosenson Journal: Cardiovasc Res Date: 2018-07-01 Impact factor: 10.787
Authors: Laura E Russell; Marianne K DeGorter; Richard H Ho; Brenda F Leake; Crystal L Schmerk; Sara E Mansell; Richard B Kim Journal: AAPS J Date: 2021-01-06 Impact factor: 4.009
Authors: Najmeh Ahangari; Mohammad Doosti; Majid Ghayour Mobarhan; Amirhossein Sahebkar; Gordon A Ferns; Alireza Pasdar Journal: Ann Med Date: 2020-08-24 Impact factor: 4.709
Authors: G Klose; F U Beil; H Dieplinger; A von Eckardstein; B Föger; I Gouni-Berthold; W Koenig; G M Kostner; U Landmesser; U Laufs; F Leistikow; W März; M Merkel; D Müller-Wieland; G Noll; K G Parhofer; B Paulweber; W Riesen; J R Schaefer; E Steinhagen-Thiessen; A Steinmetz; H Toplak; C Wanner; E Windler Journal: Internist (Berl) Date: 2014-05 Impact factor: 0.743
Authors: Laurette van Boheemen; Susan E Tett; Evelien Sohl; Jacqueline G Hugtenburg; Natasja M van Schoor; G M E E Peeters Journal: Drugs Aging Date: 2016-06 Impact factor: 3.923